Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels

References

• Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology. 2011;140:1704–1712.
   PubMed Web of Science ®Google Scholar
• Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273–290.
   PubMed Web of Science ®Google Scholar
• Moustou AE, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486–504.
   PubMed Web of Science ®Google Scholar
• Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol. 2003;48:805–821.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am. J. Gastroenterol. 2011;106:110–119.
   PubMed Web of Science ®Google Scholar
• Denadai R, Teixeira FV, Steinwurz F, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7:517–524.
   PubMed Web of Science ®Google Scholar
• Iborra M, Beltrán B, Bastida G, et al. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J Crohns Colitis. 2011;5:157–161.
   PubMed Web of Science ®Google Scholar
• Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567–577.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Allez M, Malesci A, et al. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:921–927.
   PubMed Web of Science ®Google Scholar
• Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA. 2005;102:3372–3377.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Bjerrum JT, Seidelin JB, et al. Biological treatment of Crohn's disease. Dig Dis. 2012;30:121–133.
   PubMed Web of Science ®Google Scholar
• Brandse JF, Vos LM, Jansen J, et al. Serum concentration of anti-TNF antibodies, adverse effects and quality of life in patients with inflammatory bowel disease in remission on maintenance treatment. J Crohns Colitis. 2015;9:973–981.
   PubMed Web of Science ®Google Scholar
• Coutzac C, Chapuis J, Poullenot F, et al. Association between infliximab trough levels and the occurrence of paradoxical manifestations in patients with inflammatory bowel disease: a case-control study. J Crohns Colitis. 2015;9:982–987.
   PubMed Web of Science ®Google Scholar
• Afzali A, Wheat CL, Hu JK, et al. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8:480–488.
   PubMed Web of Science ®Google Scholar
• Robinson A, Kardos M, Kimball AB. Physician global assessment (PGA) and psoriasis area and severity index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66:369–375.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.
   PubMed Web of Science ®Google Scholar
• Pittet V, Juillerat P, Mottet C, et al. Cohort profile: the Swiss inflammatory bowel disease cohort study (SIBDCS). Int J Epidemiol. 2009;38:922–931.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol. 2011;46:310–318.
   PubMed Web of Science ®Google Scholar
• Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41:199–204.
   PubMed Web of Science ®Google Scholar
• Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol. 1982;106:323–330.
   PubMed Web of Science ®Google Scholar
• Collamer AN, Guerrero KT, Henning, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996–1001.
   PubMed Web of Science ®Google Scholar
• Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100–108.
   PubMed Web of Science ®Google Scholar
• Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British society for rheumatology biologics register. Ann Rheum Dis. 2009;68:209–215.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048–1055.
   PubMed Web of Science ®Google Scholar
• Torres J, Buche S, Delaporte E, et al. Skin side effects of inflammatory bowel disease therapy. Inflamm Bowel Dis. 2013;19:1086–1098.
   PubMed Web of Science ®Google Scholar
• Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6:518–523.
   PubMed Web of Science ®Google Scholar
• Cleynen I, Van Moerkercke W, Juergens M, et al. Anti TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors. Gut. 2010;59:A1.
   PubMed Web of Science ®Google Scholar
• Michaelsson G, Kajermo U, Michaëlsson A, et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol. 2005;153:1243–1244.
   PubMed Web of Science ®Google Scholar
• Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature . Aliment Pharmacol Ther. 2011;34:1318–1327.
   PubMed Web of Science ®Google Scholar
• Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40–47.
   PubMed Web of Science ®Google Scholar